BioSpace News Archive

Crohn’s and Colitis Canada is pleased to announce a $1 million PIONEER Grant from Takeda Canada, which will support the Canadian Inflammatory Bowel Disease Research Consortium.

According to Emergen Research, the global research antibodies market size was USD 3,354.2 million in 2019 and is expected to reach USD 5,325.8 million in 2027 and register a revenue CAGR of 5.9% during the forecast period, 2020-2027.

The industry analysis report is considered a valuable source of information about the global Ambulatory Surgery Center (ASC) industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

The industry analysis report is considered a valuable source of information about the global EEG and ECG Biometrics industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

The global Sodium Hypophosphite market research report is a comprehensive report published by Reports and Data that evaluates the market size and share, growth opportunities, risks and limitations, and market growth curve.

Nuvo Group, a leader in modern maternal-fetal health, today presented new clinical data for INVUTM, the only FDA-cleared, prescription-initiated, remote pregnancy monitoring and management platform, at the Society for Maternal Fetal Medicine (SMFM)'s 42nd Annual Pregnancy Meeting.

A region crossing the folded surface of the top of the brain, called the dorsal precentral gyrus, plays an essential role in how people use the sound of their voices to control how they want the words to sound, a new study shows.

Bon Secours Liver Institute of Richmond is enrolling participants into RESPONSE, a global phase 3 clinical research study evaluating the safety and efficacy of seladelpar, an investigational drug for people already diagnosed with PBC who have been using ursodeoxycholic acid (also known as UDCA or ursodiol) but have not achieved the recommended treatment goal or cannot tolerate UDCA.

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, applauds the Biden Administration’s announcement to reignite the Cancer Moonshot with renewed White House leadership of this effort.

APTI is pleased to report that, after operational advancements and continued antibody-drug conjugate (ADC) platform development and validation in 2021, 2022 is expected to be a transformational year.